The treatment of BRAF mutation-positive unresectable or metastatic malignant melanoma has been transformed by the development of immune checkpoint inhibitors (e.g., Keytruda, Opdivo, Tecentriq) and…
Despite considerable progress in the treatment of HR-positive/HER2-negative metastatic breast cancer, the disease remains incurable. The approval and availability of the CDK4/6 inhibitors (Pfizer…
The primary goal of hemophilia A treatment is to prevent bleeding. Hemophilia A patients are a heterogeneous cohort; the tendency to bleed is highly individual. Currently available treatments…
The oral type 2 diabetes (T2D) drug market is expected to grow, fueled by rising prevalence and an increasing aging population. Owing to the risk of proteinuria, cardiovascular (CV) complications,…